

THESIS

Submitted for Partial Fulfillment of M.D. Degree in Rheumatology & Rehabilitation

Presented By
Rasha Mahmoud El-Refai
M.B.B.Ch, (M.Sc.), Cairo University

Supervisors

Prof. Dr. Nashwa Taher Allam

Professor of Rheumatology & Rehabilitation Faculty of Medicine Cairo University

Prof. Dr. Zeineb Osman Nawito

Assistant Professor of Rheumatology & Rehabilitation
Faculty of Medicine
Cairo University

Prof. Dr. Leila Ahmed Rashed

Assistant Professor of Biochemistry
Faculty of Medicine
Cairo University

Prof. Dr. Hesham Gaber El-Anany

Assistant Professor of Gynecology & Obstetrics
Faculty of Medicine
Cairo University

Faculty of Medicine, Cairo University 2010



Abstract

Systemic lupus erythematosus is a chronic, multisystem, inflammatory autoimmune disease of unknown origin characterized by the production of nonorgan-specific auto-antibodies and a broad spectrum of clinical and immunological manifestations. This study was conducted to assess the association of cytochrome P450 polymorphism with ovarian toxicity and clinical response in patients with systemic lupus erythematosus treated with intravenous pulse cyclophosphamide. Forty seven SLE patients and twenty control subjects were included in this study. The association between cytochrome P450 (CYP2C19) genotypes and the incidence of ovarian toxicity in SLE patients was significant. Also, the association between cytochrome P450 genotypes of SLE patients and their hormonal levels was highly significant.

Key words:

- Systemic lupus Enythematosus,
- Cytochrome P450.
- Polymorphism.
- Ovarian toxicity.

ACKNOWLEDGEMENTS

First and foremost thanks to "God", without his help, this work would have not been fulfilled.

I would like to express my sincere gratitude to my family and my bushand for their continuous support, endless help and encouragement.

I would like to express my deepest appreciation to Prof. Dr. Nashwa Taher Allam Professor of Rheumatology and Rehabilitation, Cairo University, not only for her valuable supervision and great help throughout the study but also for her constant support, encouragement and patience to produce this work in its

present form.

I am greatly indebted and grateful to A. Prof. Dr. Zeinab O. Nawito Assistant professor of Rheumatology and Rehabilitation, Cairo University, for devoting part of her precious time and her valuable experience and for her generous guidance, supervision, kindness, and support throughout the process of producing this work.

I feel much obliged to A. Prof. Dr. Laila Ahmed Rashed, Assistant Professor of Biochemistry, Faculty of Medicine, Cairo University, for her great help, cooperation and encouragement.

I would like to express my deepest gratitude to A. Prof Dr. Hesham Gaber Al-Enany Assistant professor of Gynecology and Obstetrics, Cairo University, for his outstanding effort and unlimited co-operation in supervising this work. He has generously offered me much of his time, valuable advice and encouragement.

I would like to express my deepest gratitude to Prof, Dr, Fawkia Mohamed Mursi Professor of Rheumatology and Rehabilitation, Cairo University for her faithful encouragement and fruitful guidance throughout my life.

Finally, I am very grateful to all my staff members and my colleagues in the department of pediatrics, Cairo University for their bely and support throughout the course of the work.

CONTENTS

	Page
Introduction & Aim of the Work	1
Review of Literature	
Chapter (1):	
Systemic Lupus Erythematosus (SLE)	4
Chapter (2):	
The Ovary	12
Chapter (3):	
Cytochrome P450	28
Chapter (4):	
Cyclophosphamide in SLE	49
Patients & Methods	63
Results	79
Discussion	96
Conclusions & Recommendations	104
Summary	106
References	108
Arabic Summary	

LIST OF TABLES

Tables		Page				
1	Environmental Factors That May Play a Role in the	9				
	Pathogenesis of Systemic Lupus Erythematosus (SLE)					
2	American College of Rheumatology Revised	10				
	Classification Criteria for Systemic Lupus					
	Erythematosus					
2	Advantages and disadvantages of fertility-preserving	26				
3	strategies					
4	Consequences of polymorphic drug metabolism					
_	Common pharmacogenetic polymorphism in cytochrome	34				
5	P450 enzymes					
6	Some important relationships between drugs and	37				
U	cytochrome P450 (CYP) enzyme					
7	Genetics of CYP2D6					
8	CYP2C19 substrates, inhibitors and inducers					
	Typical National Institute of Health-Derived Protocol for	53				
9	the management of lupus nephritis with intravenous					
	pulse cyclophosphamide					
10	Systemic lupus activity measure (SLAM)					
11	Primers and Restriction enzyme used in RFLP study of	73				
11	CYP2C19 polymorphism					
12	Demographic features of patients under study (n=47)	79				
13	Frequencies of clinical features among patients under	81				
13	study (n=47)					
14	Laboratory features of patients under study (n=47)	82				

15	Frequencies of ovarian toxicities among patients under				
	study	83			
16	Frequencies of hormonal levels among patients under	84			
	study (n=47)	04			
17	Values of various hormonal levels among patients under	05			
	study	85			
18	Frequencies of occurrence of genotypes of cytochrome	07			
	P450 (CYP2C19) among patients and control	87			
	Comparison between patients with and without ovarian				
19	toxicity as regards their clinical and demographic	88			
	features				
20	Comparison between the frequency of clinical data				
	among patients under study according to the presence or	89			
	absence of ovarian toxicity				
21	Comparison between patients with and without ovarian	n			
	toxicity as regards their laboratory features	90			

LIST OF FIGURES

Figures		Page						
1	Overview of the stages and pathogenesis of systemic lupus erythematosus (SLE).							
2	Functional anatomy and developmental changes in the adult ovary during an ovarian cycle							
3	Endocrine interactions in the female reproductive axis							
4	The idealized cyclic changes observed in gonadotropins							
5	A suggested pathophysiologic mechanism of chemotherapy-induced gonadotoxicity							
6	Catalytic cycle of P450 enzymes							
7	The metabolism of cyclophosphamide							
8	Cyclophosphamide formulations.							
9	Frequencies of ovarian toxicity among patients under study							
10	Frequencies of hormonal levels among patients under study							
11	An agarose gel electrophoresis showing PCR products of CYP2C19							
12	Frequencies of occurrence of genotypes of cytochrome P450 (CYP2C19) among patients under study.							
13	Frequencies of occurrence of genotypes of cytochrome P450 (CYP2C19) among the control: (n=20)							
14	Association between SLE patients receiving cyclophosphamide over a duration of less than 18 months and those receiving cyclophosphamide over a duration of 18 months or more and the incidence of ovarian toxicity	91						

	Association	between	SLE	patients	receiving		
	cyclophosphamide over a duration less than 18months					92	
15	and those receiving cyclophosphamide over a duration			92			
	of 18 months or more and their hormonal levels.						
	Association be	tween ge	notypes	of cytochr	rome P450		
16	(CYP2C19) of	SLE pati	ents and	incidence	of ovarian	94	
	toxicity among	them.					
17	Association be	tween ge	notypes	of cytochr	rome P450	05	
	(CYP2C19) of S	SLE patier	nts and th	eir hormon	al levels.	95	

LIST OF ABBREVIATIONS

ACR American College of Rheumatology

ADR Adverse Drug Reactions

ALT Alanine Transaminase

ANA Antineuclear Antibody

AST Aspartate Transaminase

BMT Bone Marrow Transplant

CNS Central Nervous System

CrCl Creatinine Clearance

CYC Cyclophosphamide

CYP Cytochrome P 450

E Estrogen

E2 Estradiol

EBV Ebstein-Barr Virus

ECG Electrocardiogram

ESR Erythrocyte Sedimentation Rate

ESRD End Stage Renal Disease

Fig Figure

FSH Follicle Stimulating Hormone

GERD Gastro-Esophageal Reflux Disease

GnRH Gonadotropin Releasing Hormone

GnRHα Gonadotropin Releasing Hormone Agonist

Hb Hemoglobin

Hct Hematocrite

HLA Human Leukocytic Antigen

hr hour

HT Hormone Replacement

Inh A Inhibin A

Inh B Inhibin B

IUD Intra uterine Device

IVF Invitro Fertilization

IVM Invitro Maturation

L Litre

LH Leutinizing Hormone

Max Maximum

mg milligram

Min Minimum

ml Milliliter

N Number

P Progesterone

PCR Polymerase Chain Reaction

RBC Red Blood Cell

RFLP Restriction Fragment Length Polymorphism

SD Standard Deviation

SLAM Systemic Lupus Activity Measure

SLE Systemic Lupus Erythematosus

SNP Single nucleotide Polymorphism

TBA Total Body Area

TIA Transient ischemic attack

TLC Total Leukocytic Count

TRM Transplant Related Mortality

UV Ultraviolet

WBC White Blood cell

wt wild type

yrs years

Introduction

Systemic lupus erythematosus (SLE) is a chronic usually life-long, autoimmune disease, characterized by exacerbations and remissions. The hallmark of the disease is the immune system deregulation resulting in the production of nonorgan specific autoantibody (ANA), generation of circulating immune complexes and activation of the complement system (*Katsifis and Tzioufas*, 2004).

Women and minorities are disproportionately affected and SLE is most common in women of childbearing age (*Boumpas et al.*, 1993).

Therapy with cyclophosphamide (CYC) is required in 15-20% of patients with SLE with major organ disease (*Singh et al.*, 2007). Pulsed intravenous CYC is considered as a standard therapy for lupus nephritis and several other manifestations of SLE. While the response rate to intravenous cyclophosphamide is substantial, concern has arisen about its toxicity. In addition to increased susceptibility to infections, bone marrow suppression, alopecia, hemorrhagic cystitis and malignancy, ovarian failure is an important side effect associated with the use of cyclophosphamide (*Ioanidis et al.*, 2002).

Cyclophosphamide is an oxaphospharine alkylating agent with cytotoxic and immunosuppressive effects. Cyclophosphamide itself is not cytotoxic but it is enzymatically converted by hepatic microsomal enzymes cytochrome P450 (CYP) to multiple metabolites (*Tsokos*, 1987).

Several CYP are implicated in metabolism of CYC. The enzymes CYP2B6 and CYP2C19 are genetically polymorphic and are known to have variant alleles, resulting in wide interpatient variability on exposure to cyclophosphamide (*Lang et al.*, 2001).

Ovarian toxicity is of major concern in premenopausal women receiving CYC, and 12-59% develop premature ovarian failure (*Huoang et al., 2002*). Younger patients and lower cumulative dose of CYC are associated with lower risk of ovarian failure (*McDermott and Powell, 1996*). Genotyping, therefore, may be used to identify patients who are at higher risk of premature ovarian failure (*Takada et al., 2004*). Cotreatment with gonadotropin-releasing hormone agonists may preserve future fertility and ovarian function in these young women. Ovarian banking before administration of cyclophosphamide should be considered in selected patients (*Katsifis and Tzioufas, 2004*).

Aim of the work

The aim of the work is to study the association of cytochrome P450 (CYP2C19) genetic polymorphism with ovarian toxicity and clinical response in patients with systemic lupus erythematosus (SLE) treated with intravenous pulse cyclophosphamide.

Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus is a prototypic autoimmune disease characterized by the production of auto-antibodies to components of the cell nucleus in association with diverse clinical manifestations encompassing all organ systems (*Pisetsky*, 2008).

SLE primarily is a disease of young women, with a peak incidence between the ages of 15 and 40 and a female: male ratio of 6 to 10 : 1 (*Pisetsky*, 2008).

SLE affects approximately 1 in 1000 to 2500 in the general population, but disease incidence in African American and Latino women is much higher (up to one in 250 in African American women between the ages of 18 to 65 years). The 5-year survival after diagnosis is 90% (*Gravel et al.*, 2007).

The extreme heterogeneity of the disease has led some investigators to propose that SLE represents a syndrome rather than a single disease (*Tassiulas and Boumpas*, 2009).

Pathogenesis:

The pathogenesis of systemic lupus erythematosus (SLE) is complex, as shown in **Fig. (1).**




Fig. (1): Overview of the stages and pathogenesis of systemic lupus erythematosus (SLE). The immune abnormalities that characterize SLE are pictured in five phases. In phase 1, an individual is susceptible to SLE because of genetics, gender, and the external environment that influences antigen presentation and other immune responses. In an individual with adequate numbers of predisposing factors, stage 2 develops, consisting of abnormal persistence of antigens, including hypomethylated DNA (CpG DNA) in DNA/anti-DNA complexes, and other DNA/protein and RNA/protein selfantigens. These antigens activate cells of innate (dendritic cells [DC]) and adaptive (B-cells) immune systems via Toll-like receptors (TLR); the activated cells then activate T lymphocytes. The adaptive system is working at the same time, where antigen presenting cells (APC) present self-antigens to Tlymphocytes and B lymphocytes; the B cells mature to plasma cells and secrete autoantibodies. At the same time, suppressive networks (regulatory and inhibitory T cells, phagocytic cells, idiotypic networks) are in place to dampen the harmful immune responses. Phase 3 begins with a clinically healthy individual having positive tests for autoantibodies in the serum. Immune complexes form. Phase 4, following phase 3 by a mean of 3 years, is clinical disease. The result of complement activation and proinflammatory responses from tissue attacked by autoantibodies and immune complexes causes symptoms and signs of disease, which can include the features listed in the figure. Phase 5 occurs after months and years of chronic inflammation and chronic oxidative damage, which promote scarring of tissue such as kidney and lung, plaque deposition in arteries, and clotting. Irreversible tissue damage occurs. It is likely that at each of these phases, some individuals progress to the next phase, and others do not. CNS, central nervous system; EBV, Epstein-Barr virus; UV, ultraviolet (Hahn and Tsao, 2009).